French Firm Explores U.S. Regulatory Strategy For Blood-based Alzheimer’s Test
This article was originally published in The Pink Sheet Daily
Executive Summary
With a CE mark in hand, Exonhit is training its sights on the U.S. market. A 160-patient pilot study conducted through the Cleveland Clinic completed enrollment a few weeks ago.
You may also be interested in...
Research In Brief
St. Jude Medical reports updated Riata defibrillator lead data. Alzheimer’s RNA-based blood test studies make progress. More research news.
HHS Gives Nod To Diagnostics In Healthy People 2020 Initiative
More people would be screened for health conditions ranging from diabetes to colorectal cancer to sleep apnea over the next decade under goals set out in HHS’ recent “Healthy People 2020” initiative.
CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously
Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.